HELIOSPECTRA AB Redeye provides an update following Heliospectra’s Q2’23 report. We find the margin improvements, combined with a stronger-than-expected top line, to be encouraging. However, order intake fell short of our expectations, implying a weaker Dutch market and a mixed outlook in the near term. We have made a few minor changes to our near-term estimates. Our fair value range, however, remains unchanged, with a base case of
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/
© Modular Finance, source
